Samarth Kulkarni - Feb 18, 2022 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Role: Chief Executive Officer, Director
Signature: /s/ Michael Esposito, attorney-in-fact
Stock symbol: CRSP
Transactions as of: Feb 18, 2022
Transactions value $: $0
Form type: 4
Date filed: 2/22/2022, 04:43 PM
Previous filing: Dec 22, 2021
Next filing: Mar 14, 2022
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CRSP	Stock Option (Right to Buy)	Award	$0	+115K		$0.00	115K	Feb 18, 2022	Common Shares	115K	$58.29	Direct	F1
transaction	CRSP	Restricted Stock Units	Award	$0	+53K		$0.00	53K	Feb 18, 2022	Common Shares	53K		Direct	F2, F3

Showing 1 to 2 of 2 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This option was granted on February 18, 2022 with respect to 115,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of March 18, 2022.
F2	Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
F3	This restricted stock unit award was granted on February 18, 2022 with respect to 53,000 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026.